Loading Events
  • This event has passed.

Closing the Loop for Lupus: A Wellness Toolkit for Women

December 5, 2022 @ 3:00 pm - 4:00 pm EST

Lupus is a chronic autoimmune disease characterized by widespread inflammation that often results in damage to the joints, skin, brain, lungs, kidneys and blood vessels. An estimated 1.5 million Americans have some form of lupus, and 90% are women between the ages of 15 and 44. Lupus is more prevalent among women of color, who also develop symptoms at younger ages and have more severe symptoms and complications from the disease.Systemic lupus erythematosus (SLE) is the most common type of lupus, affecting multiple parts of the body, and cutaneouslupus erythematosus (CLE) primarily affects theskin. Because the symptoms of lupus mimic other diseases, a majority of patients are initially misdiagnosed, and it can take up to 6 years and seeing multiplehealth care specialists before receiving an accurate diagnosis. Women living with lupus have a greater risk for developing other chronic conditions, such as heart disease and osteoporosis, or lupus nephritis due to kidney inflammation and damage. Although lupus does not affect fertility, pregnant women should be aware of potential complications, such as preeclampsia.

There is no cure for lupus, and the limited treatments available primarily focus on reducing symptom flares, resulting in insufficiently improved health outcomes.There is a pressing need to address gaps in research and clinical education, and to develop policy solutions that will eliminate barriers to access for treatments and quality care for women.

SWHR hosted a series of webinars to share educational information about the impact of lupus on women’s health.The events discussed how to improve health outcomes through recognizing and addressing symptoms, comorbidities, treatment options, and barriers to accessing quality care, while highlighting the diverse experiences of women living with lupus.

The SWHR Closing the Loop for Lupus series includes:

Follow the conversation on Twitter at @SWHR and #SWHRtalksLupus.

This event is free and open to the public.


December 5, 2022
3:00 pm - 4:00 pm EST
Event Categories:
, , , ,




  • Introduce autoimmune diseases and lupus, and their impacts on women
  • Provide a holistic overview of treatment options for patients (including lifestyle and CAM approaches) and key considerations for chronic disease management
  • Highlight information and wellness strategies from SWHR’s lupus patient toolkit
  • Emphasize opportunities for women to improve their quality of care and overall health throughout the lifespan

Download Your Copy of the Toolkit!


Anca Askanase, MD, MPH
Professor of Medicine, Columbia University
Anca Askanase, MD, MPH
Professor of Medicine, Columbia University

Dr. Askanase is the founder and director of the Columbia University Lupus Center and the Director of Rheumatology Clinical Trials. She is an internationally renowned clinician, diagnostician, and researcher with more than 20 years specializing in complex systemic lupus erythematosus (SLE). Dr. Askanase trained as a rheumatologist at New York University, where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging SLE cases before moving to her current position at Columbia University Irving Medical Center. Dr. Askanase’s academic career has focused primarily on patients with SLE and other autoimmune diseases. In addition to authoring numerous publications and her involvement in benchmark clinical trials, Dr. Askanase is a member of several major international consortia aimed at providing the collaboration between lupus doctors needing to improve outcomes and therapies in lupus: the SLICC (SLE international Collaborating Clinics), the LNTN (Lupus Nephritis Trial Network), and the Lupus Clinical Investigators Network (LuCIN). One of her most rewarding experiences was her involvement in the studies that led to the FDA approval of belimumab, anifrolumab, and voclosporin. Dr. Askanase is also involved in the development and testing of new SLE outcome measures, telemedicine outcomes, new imaging methods for lupus arthritis, and interventions to improve clinical trial participation for disparate population as ways to improve the care and outcomes of lupus patients. 

Rosalind Ramsey-Goldman, MD, DrPH
Professor of Medicine, Northwestern University Feinberg School of Medicine 
Rosalind Ramsey-Goldman, MD, DrPH
Professor of Medicine, Northwestern University Feinberg School of Medicine 

Rosalind Ramsey-Goldman, MD, DrPH, is the Gallagher Research Professor of Rheumatology at Northwestern University Feinberg School of Medicine (NUFSM) and an attending physician for Northwestern Medicine. She is the director of the Patient-Oriented Clinical Research Program in lupus with continuous funding from NIH, foundations, philanthropy, and industry since 1991 when she joined the faculty at NUFSM. Her research program examines risk factors to minimize complications in lupus including osteoporosis, malignancy, renal, and cardiovascular disease. Through national and international collaborations, she studies genetic risk factors for disease severity/susceptibility; collaborates on investigations studying pathogenesis of disease; develops disease classification criteria, flare assessments, nephritis guidelines, disease impact (damage and frailty), and assessment of patient-reported outcomes (including an investigator-initiated NIAMS/NIH funded clinical trial testing an intervention to mitigate fatigue, a pervasive problem affecting 90% of patients with lupus).  She is active in designing, monitoring, and performing clinical trials, identifying novel biomarkers, and testing innovative therapies. Many of these clinical investigations incorporate analysis of lupus in multiethnic cohorts examining clinical, laboratory, and health related outcomes. An underlying theme for these investigations is a longstanding interest in documenting health disparities in lupus and experience working with communities.  

Estela Mata-Carcamo
President, Looms for Lupus 
Estela Mata-Carcamo
President, Looms for Lupus 

Estela Mata-Carcamo is a tireless advocate for health equity, leading transformative initiatives at the intersection of healthcare, community engagement, and patient empowerment. As the President and Co-founder of Looms for Lupus, she drives awareness and support for lupus, fibromyalgia, and mental health. Her leadership has positively impacted thousands of patients and caregivers through education, advocacy and support.

Estela engages with the community, empowering patients to use their voices, share their stories, and shape policy decisions. She is also an ambassador of hope and co-founder of Mata Advocacy and Support (MAS), an advocacy consulting firm dedicated to making a positive impact in the community.

With 30 years of healthcare experience, Estela bridges connections between all stakeholders: industry and patients alike. Fluent in both English and Spanish, she collaborates globally with entities such as the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration. Estela actively participates in Congresswoman Grace Napolitano’s Mental Health Consortium and serves as Vice-Chair of the Board for the California Chronic Care Coalition.



SWHR’s Lupus Program is supported by educational sponsorships by Aurinia Pharmaceuticals and Eli Lilly & Company. SWHR maintains editorial control and independence over educational content.